NAMPT

NAMPT (Nicotinamide Phosphoribosyltransferase)

Overview

Nicotinamide phosphoribosyltransferase (NAMPT), also known as visfatin, is a rate-limiting enzyme in the NAD+ salvage pathway, catalyzing the conversion of nicotinamide to nicotinamide mononucleotide 42406471Jul. As a critical metabolic enzyme, NAMPT plays an essential role in maintaining cellular NAD+ levels, which are required for numerous metabolic and signaling processes. In cancer, particularly triple-negative breast cancer (TNBC), NAMPT is frequently upregulated to meet the increased bioenergetic and biosynthetic demands of rapidly proliferating tumor cells 42269602Jun. Beyond its role in malignancy, NAMPT expression is also associated with metabolic disorders including type 2 diabetes mellitus and autoimmune thyroid disease, reflecting its broader significance in systemic metabolism and immune regulation. These multiple disease associations, coupled with its metabolic essentiality in cancer cells, have positioned NAMPT as an increasingly promising therapeutic target for drug discovery.

Recent Publications Summary

Recent research has demonstrated that NAMPT represents a viable therapeutic target across multiple cancer types and therapeutic modalities. Integrated multiomics analyses combining RNA-sequencing and mass spectrometry-based proteomics identified NAMPT as the primary molecular target of emodepside, an anticancer compound with potential therapeutic efficacy in triple-negative breast cancer 42486779Jul.

A series of novel targeted protein degradation approaches have been developed specifically for NAMPT. The Protein-Radical-Oxidation Targeting Enediyne Chimera (PROTEC) platform has been applied to design chimeric enediyne compounds capable of degrading nicotinamide phosphoribosyltransferase through a radical clock mechanism, thereby enhancing cytotoxicity against cancer cells 42504523Jul. Complementary work has identified potent NAMPT-targeting PROTAC (proteolysis-targeting chimera) degraders that suppress triple-negative breast cancer through macrophage reprogramming, leveraging the enzyme's metabolic role in the tumor microenvironment 42406471Jul.

Combination therapeutic strategies targeting NAMPT have shown promise for overcoming treatment resistance. A dual inhibitor simultaneously targeting MLK3 and NAMPT was developed for triple-negative breast cancer, with NAMPT inhibition addressing the increased NAD+ demand characteristic of TNBC 42269602Jun. Similarly, novel dual small-molecule inhibitors targeting both SHP2 (protein tyrosine phosphatase non-receptor type 11) and NAMPT were identified as a strategy for overcoming resistance to allosteric SHP2 inhibition in tumor cells 42324937Jun. More recently, 4-arylindolines bearing a pyrido[3,2-d]pyrimidine scaffold were designed as dual inhibitors targeting both the PD-1/PD-L1 axis and NAMPT, representing an approach to overcome resistance to immune checkpoint blockade by simultaneously modulating tumor immunoevasion and metabolic metabolism 42366729Jun.

Beyond oncology, NAMPT expression has been examined in metabolic and autoimmune contexts. Adipocytokine profiling studies, including assessment of visfatin (NAMPT), revealed altered adiponectin and resistin levels in adults with type 2 diabetes mellitus and autoimmune thyroid disease, with distinct associations between adipokine expression and metabolic, hormonal, and thyroid parameters 42455070Jul. Additionally, proteomic investigations of obstructive sleep apnea patients identified differential protein expression patterns, including metabolic enzymes, though NAMPT was among proteins showing altered expression in association with periodontal destruction 42057688Apr.

What Changes, What Holds

1. Emodepside demonstrates direct targeting of NAMPT in triple-negative breast cancer
REINFORCES Emodepside's mechanism as a NAMPT inhibitor, identified through multiomics profiling 42486779Jul, validates the therapeutic targetability already established in the baseline. This finding confirms NAMPT can be chemically inhibited without revealing new mechanisms, disease contexts, or evidence challenging existing therapeutic positioning.

2. Protein degradation approaches targeting NAMPT suppress cancer through tumor microenvironment remodeling
NEW DIRECTION PROTEC and PROTAC platforms achieve NAMPT degradation 42504523Jul42406471Jul, with PROTAC degraders suppressing TNBC by reprogramming macrophages in the tumor microenvironment. The Overview describes only direct metabolic roles, not tumor immune cell involvement or microenvironmental mechanisms, making this an expansion of NAMPT's therapeutic function beyond cancer cell metabolic suppression.

3. Combination targeting of NAMPT with other kinases overcomes acquired therapeutic resistance
NEW DIRECTION Dual inhibitors pairing NAMPT with MLK3 42269602Jun, SHP2 42324937Jun, or immune checkpoint molecules 42366729Jun address treatment-resistant disease through metabolic-immunological coordination, a therapeutic challenge the Overview does not acknowledge. NAMPT inhibition alone appears insufficient; these findings position combination strategies targeting metabolic enzymes alongside signaling and checkpoint pathways as necessary for durable therapeutic effect in cancer.

4. NAMPT expression associates with periodontal destruction in obstructive sleep apnea
NEW DIRECTION Proteomic profiling in obstructive sleep apnea identified differential NAMPT expression correlating with periodontal damage 42057688Apr, establishing disease associations the Overview does not address. Concurrent adipocytokine analysis reinforced existing diabetes and thyroid disease links 42455070Jul, though the sleep apnea finding introduces NAMPT to an unexpected inflammatory and metabolic syndrome context.

Overview update candidates: protein degradation platforms and combination strategies for overcoming therapeutic resistance.